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Subunit vaccines use delivery platforms to present minimal antigenic components for 
immunization. The benefits of such systems include multivalency, self-adjuvanting properties and 
more specific immune responses. Previously, we have reported the design, synthesis and 
characterization of self-assembling peptide cages (SAGEs). In these, de novo peptides are combined 
to make hubs that assemble into nanoparticles when mixed in aqueous solution. Here we show that 
SAGEs are non-toxic particles with potential as accessible synthetic peptide scaffolds for the 
delivery of immunogenic components. To this end, SAGEs functionalized with the model antigenic 
peptides tetanus toxoid632-651 and ovalbumin323-339 drive antigen-specific responses both in vitro and 
in vivo, eliciting both CD4+ T cell and B cell responses. Additionally, SAGEs functionalized with 
the antigenic peptide hemagglutinin518-526 from the influenza virus are also able to drive a CD8
+ T 
cell response in vivo. This work demonstrates the potential of SAGEs to act as a modular scaffold 




Vaccines have been pivotal to the development of modern medicine, from general childhood 
vaccination to the global eradication of smallpox and near elimination of polio. Nonetheless, 
successful vaccines for major targets such as malaria and human immunodeficiency virus (HIV) 
have yet to be established,[1] and the recent Zika virus outbreak highlights the need for ongoing 
vaccine development.[2] Related to this, there is a global rise in antimicrobial resistance, and so 
relying on medication alone to treat a disease once contracted is not a guaranteed option.[3] Thus, 
continued vaccine development is still an important area of both basic and applied research.[4] 
Traditional vaccines, based on the administration of killed or attenuated organisms or their 
purified components, have proven to be amongst the most effective methods for disease 
prevention.[5] However, a number of safety issues relating to the production and administration of 
 
 
these vaccines limit their universal application, including: the risk of reversion to a virulent 
organism; decreased or altered immune response after inactivation; the possibility of causing 
disease in immune compromised individuals; and the requirement to maintain the cold chain.[6] 
Recent advances in the identification of single components (antigens) capable of generating 
protective immunity has driven the development of subunit vaccines, where instead of using whole 
pathogens, specific portions are delivered using a scaffold.[7] Furthermore, improved genetic 
methods and expression systems have resulted in cheaper and large-scale production of recombinant 
microbial antigens without the need to culture highly pathogenic infectious agents.[8]  
Despite these advantages, recombinant subunit vaccines are often less immunogenic than 
their traditional whole-organism counterparts. To overcome decreased immunogenicity, subunit 
vaccines require the addition of immunostimulatory agents, i.e. adjuvants,[9] or optimization of 
delivery systems that specifically target immune cells and tailor immune responses.[10] Another key 
strategy for subunit vaccine design is to create a multivalent platform enabling the expression of 
multiple antigens in a repetitive array.[11] Having a delivery system with several copies of T- and B-
cell antigens from different strains of the pathogen could generate cross-protective immunity and 
increase the immunogenicity of the vaccine. If required, these platforms could be adapted to display 
both antigens and immunopotentiators, such as Toll-like receptor (TLR) agonists,[12] thus enhancing 
the activity, uptake and presentation of antigens to the immune system. Adopting strategies that 
direct antigen delivery and release may stimulate more potent immune responses using lower doses 
of weak immunogens. Reducing the need for the prime and boost strategies often required in 
conventional vaccination regimens would lead to dose-sparing, beneficial for reducing development 
cost and improving immunization efficiency schedules in the event of vaccine shortages.[13] 
Subunit vaccine delivery systems typically include the use of liposomes,[14] virus-like 
particles[15] or peptide nanoparticles.[16] The rationale is that these mimic the size and shape of 
viruses to simulate an immune response similar to a live attenuated vaccine, whilst maintaining the 
selectivity of a subunit vaccine. Protein engineering and design approaches, in particular, provide 
 
 
increased synthetic access and control of components,[17] with one example being the self-
assembling protein nanoparticle (SAPN) platform.[18] SAPNs comprise trimeric and pentameric α-
helical coiled-coil motifs linked in a single peptide. These polypeptides assemble into particles 
approximately 20 nm in diameter. They have been optimized to act as vaccine carriers, and their 
biodistribution in vivo has been monitored.[19] They can serve as repetitive antigen displays capable 
of inducing a variety of immune responses, and include particles modified with epitopes derived 
from severe acute respiratory syndrome coronavirus,[20] malaria,[21] HIV[22] and influenza virus.[12b] 
Other peptide-based self-assembling systems with potential as functionalized structures take on the 
form of nanofibers, or tubes, rather than resembling viral capsid architecture.[23] These assemblies 
exploit the thermal stability[24] and environmental responsiveness[25] of synthetic peptide systems, 
along with dose control[26] and the incorporation of whole-protein antigens.[27] Such examples 
demonstrate the potential of synthetic peptide- and protein-based vaccine delivery platforms. 
The work described herein explores the potential of self-assembling peptide cages (SAGEs) 
to act as modular scaffolds in a synthetic biology approach for antigen delivery. SAGEs are made 
from de novo α-helical coiled-coil peptides. Specifically, a set of homotrimeric (CC-Tri3) and 
heterodimeric (CC-Di-A and CC-Di-B) peptides are linked via a disulfide bond to form two 
complementary hubs.[28] Mixing of these hubs in aqueous solution leads to co-assembly into 
hexagonal lattices,[29] ultimately folding into spherical particles approximately 100 nm in diameter 
(Figure 1a). The working hypothesis of SAGE architecture is that each CC-Tri3 unit is oriented 
within the peptide lattice such that its N terminus faces the exterior of the particle and its C terminus 
faces the interior, while CC-Di-A and CC-Di-B have greater freedom of rotation around the 
disulfide bond.[28, 30] Subsequently, functionality can be incorporated via CC-Tri3 to allow for 
bespoke dose delivery as the antigen dose is controlled via peptide synthesis and conjugation rather 
than passive encapsulation.[31] The fully synthetic SAGE appears to withstand relatively robust 
functionalization,[31a] can be predictably modified to alter cellular uptake,[31b] and the modularity of 
the system allows for fine control of modification.[29] 
 
 
SAGEs are potentially an alternative platform for developing subunit vaccines with the 
following advantages. Their modularity means that by mixing different ratios of the hub building 
blocks we can incorporate multiple antigens, thus tailoring the immune response. Furthermore, the 
nature of the SAGE structure provides a multivalent platform which can potentially be used to 
deliver multiple antigens from different strains, thereby increasing antigen immunogenicity. 
Another important consideration is component stability. The hub building blocks can be lyophilized 
and stored as powder long-term, which could also be a benefit to such a platform by avoiding 
problems associated with the cold chain. Here, we investigate this potential of the SAGE scaffold as 
a vaccine platform, and whether SAGEs functionalized with model antigenic peptides successfully 
deliver them to drive specific immune responses. The results show that SAGEs are non-toxic and 
capable of enhancing the immune responses, in vitro and in vivo, against model antigenic peptides. 
 
 
Figure 1: SAGE assembly and design of functionalized hubs. a Schematic representation of parent 
SAGE assembly. Linking the heterodimer to the homotrimer forms complementary hubs that, when 
mixed, self-assemble into a lattice and close to form particles approximately 100 nm in diameter (as 
observed by scanning electron microscopy (SEM); scale bar = 1 µm). b Cartoons representing 
incorporation of different model antigenic peptides into hubs. Model antigenic peptides (grey ovals) 






2. Results and Discussion 
2.1. SAGEs are robust to modification with antigenic peptides 
SAGEs were functionalized with model antigenic peptides (epitopes). This was achieved by 
extending the CC-Tri3 peptide sequences with the epitopes during solid-phase peptide synthesis 
(SPPS). SAGEs were designed and synthesized with this functionality added at either the N or C 
terminus, or both termini of CC-Tri3 (Figure 1b, Tables S1-3, Figures S1-6). For in vitro work we 
used the model antigenic peptide tetanus toxoid632-651 (TT),
[32] a CD4+ T cell epitope. In vivo 
experiments used the model antigenic peptides ovalbumin323-339 (OVA),
[33] a CD4+ T cell and B-cell 
epitope, and influenza virus A/PR/8/34 (H1N1) hemagglutinin518-526,
[34] a CD8+ T cell epitope. For 
this last epitope a short, N-terminal 10-residue sequence from the herpes simplex virus DNA 
polymerase was included to maximize effective proteasomal processing and presentation by major 
histocompatibility receptor class I (MHC-I) molecules.[35] It was this extended peptide (HA) that 
was used for additional in vivo experiments. The functionalized CC-Tri3 peptides were subjected to 
biophysical characterization before being conjugated with the CC-Di-A/B peptides to make hubs. 
First, circular dichroism (CD) spectroscopy was used to test for any impact on the trimeric 
component of all functionalized trimers. To monitor the helicity of each functionalized peptide, the 
mean residue ellipticity (MRE, deg cm2 dmol-1 res−1) at 222 nm was recorded as spectra. The 
observed signals were consistent with folded CC-Tri3 appended with unfolded peptides (Figure 2a, 
Table S4). Peptide stability was not greatly altered, as observed by comparable midpoint of 
unfolding temperatures during thermal denaturation experiments (Figure 2b, Table S4). 
Functionalized hubs were similarly assessed and found to be unaffected (Figure S7 and Table S5).  
All functionalized CC-Tri3 peptides were then analyzed using sedimentation velocity 
analytical ultracentrifugation (AUC; Figure S8). The predominant peak in the TT- and HA-
functionalized peptides was trimeric, with TT-CC-Tri3-TT peptide showing an additional smaller 
species. The OVA-functionalized peptides did not appear to form discrete trimers in solution, and 
 
 
so whilst their thermal stability was not drastically altered it is possible that the addition of OVA 
affected the ability of the peptide to trimerize. 
The assembly of functionalized SAGE particles was assessed by scanning electron 
microscopy (SEM) and dynamic light scattering (DLS). By SEM, TT-functionalized SAGEs 
produced particles of comparable size to parent SAGEs, SAGE-HA formed slightly larger particles, 
and OVA-functionalized SAGEs formed much larger particles (Figure 2c-h). The data obtained 
from DLS measurements often gave a range of particle sizes within samples and it was not possible 
to determine particle size from these experiments (Figure S9). While the hydrodynamic diameter 
increased compared to that of the individual hubs, this technique demonstrated the ability of these 
particles to form aggregates. For both of these techniques the aggregation of the sample meant it 
was not possible to accurately determine particle size.  
However, overall, this suite of biophysical characterization confirms that SAGEs can be 




Figure 2: Biophysical characterization of functionalized SAGEs. a-b CD spectroscopy of 
functionalized CC-Tri3 peptides (CC-Tri3 in black, TT-CC-Tri3 in blue, CC-Tri3-TT in green, TT-
CC-Tri3-TT in red, OVA-CC-Tri3 in purple, CC-Tri3-OVA in orange, CC-Tri3-HA in pink) and 
antigenic peptides (TT in black lines, OVA in black dashes, HA in black dots). 5 °C wavelength (a) 
and thermal denaturation curves (b) of functionalized CC-Tri3 and antigenic peptides. Conditions: 
50 µM peptide in PBS (pH 7.4). c-h SEM images of assembled functionalized SAGEs: TT-SAGE 
(c), SAGE-TT (d), TT-SAGE-TT (e), OVA-SAGE (f), SAGE-OVA (g), SAGE-HA (h). Conditions: 




2.2 Parent SAGEs are non-toxic and stimulate PBMC proliferation. 
In vitro studies of SAGE uptake by HeLa cells showed them to be non-toxic,[31b] and so SAGE 
toxicity with other cell types was assessed using human peripheral blood mononuclear cells 
(PBMCs) isolated from whole blood. PBMCs were exposed to the polyclonal stimulus 
 
 
phytohemagglutinin (PHA) to induce a response indicative of T cell proliferation, in the presence or 
absence of SAGE. PBMCs were able to proliferate in response to PHA irrespective of SAGE 
concentration, confirming that the assembled particles are not toxic (Figure 3a). To assess whether 
SAGE were intrinsically immunogenic, resting PBMCs were cultured with parent SAGE at a range 
of concentrations to determine if proliferation was induced. PBMC proliferation was observed at all 
concentrations, with higher SAGE concentrations giving the greatest proliferative response (Figure 
3b). The ability of the SAGEs to stimulate PBMC proliferation may be attributed to either weak 
inherent immunogenicity or mitogenicity. 
The source of this proliferation was further probed by assaying the SAGE components, both 
the building blocks (HubA and HubB) and their constituent peptide components (CC-Tri3, CC-Di-
A and CC-Di-B). Their ability to stimulate proliferation of PBMCs was assayed (Figure 3c) along 
with an immunological memory response in human and mouse sera (Figure 3d-e). The proliferative 
response to SAGEs was not found to be due to any particular peptide component. We posit that 
SAGEs may induce this response due to their shape, size and local concentration. From these 
results, it is proposed that the ability of SAGEs to prompt low-level immune responses would be 
beneficial for their development as a vaccine delivery platform, potentially in a similar manner to 
that employed by conjugate vaccines.[36] 
SAGE toxicity in vivo was also assayed by immunizing mice with extreme doses of parent 
SAGE. BALB/c mice were immunized with four doses (350 µg) of parent SAGE, each dose at an 
interval of three weeks (two weeks for the final immunization). Serum aspartate aminotransferase 
(AST) levels, used to evaluate liver function, were comparable between SAGE-immunized (five 
mice) and control (PBS only, three mice) animals (Figure 3f), and immunization did not lead to an 
alteration in percentage lymphocyte and monocyte population numbers in peripheral blood (Figure 
S10). Immunized mice did not develop any injection site reactions or adverse systemic effects, and 
in combination with the lack of histopathological changes (Table S6) these data suggest SAGEs are 





Figure 3: Parent SAGEs are non-toxic and stimulate PBMC proliferation. a PBMC proliferation 
in response to exposure to the polyclonal stimulus PHA and increasing amounts of SAGE to assay 
SAGE toxicity. Conditions: 15 µM (solid line), 7.5 µM (dashed line) and 2 µM (dotted line) SAGE 
in PBS (pH 7.4) with PHA; 10 µg ml-1 PHA alone as positive control (filled circles); proliferation 
measured by the incorporation of 3H-thymidine, in counts per minute (cpm); n = 4 donors. b Peak 
PBMC proliferative response upon exposure to parent SAGEs alone to assay SAGE immunogenicity. 
Conditions: 15, 7.5 and 2 µM SAGE in PBS (pH 7.4); proliferation measured as before (cpm); n = 7 
donors. c Peak PBMC proliferative response upon exposure to SAGE components when incubated at 
37 °C for up to 10 days. Conditions: Components at 7.5 µM in PBS (pH 7.4); proliferation measured 
as before (cpm); n = 8 donors. d Endpoint titre of antibody in human sera recognizing parent SAGE 
and components. n = 10 donors. e Endpoint titre of antibody in mouse sera recognizing parent SAGE 
and components. n = 6.  f In vivo mouse toxicity data for parent SAGEs as analyzed by AST levels. 
BALB/c mice were immunized subcutaneously with four sequential doses of SAGE (350 µg in PBS 




2.3 Antigen presenting cells internalize but are weakly activated by parent SAGEs  
Antigen presenting cells (APCs) are immune phagocytes that internalize, process and present 
foreign material to other immune cells. After establishing that parent SAGEs are non-toxic but 
potentially immunogenic/mitogenic, we explored whether immune phagocytes internalize and are 
primed by SAGE particles. Human PBMCs were purified and differentiated into monocyte-derived 
dendritic cells (MDDCs) and macrophages (MDMs). To monitor the cellular uptake of particles, 
 
 
5 % of the hub building blocks were replaced with fluorescently labelled counterparts to assemble 
FITCSAGE (Tables S1-3). Cellular uptake was quantified by flow cytometry, isolating internalized 
fluorescence by quenching external fluorescence with trypan blue (Figure 4). Both MDDCs and 
MDMs took up SAGEs with similar kinetics, with the greatest rate of uptake in the first 60 minutes. 
However, MDMs had a greater overall uptake of SAGEs compared to MDDCs. Although MDDCs 
and MDMs are both known to be phagocytic cells, the uptake of nanoparticles can be influenced by 
particle size and aggregation state and additionally, the maturation state of the cells,[37] which may 
explain the differences in SAGE uptake observed.   
Next, we investigated whether phagocytes were activated after SAGE uptake as determined 
by the increased secretion of a range of cytokines and the increased surface expression of co-
stimulatory and antigen presenting molecules. MDDCs and MDMs were cultured with SAGEs, 
followed by the analysis of cell-surface markers and cytokines in the cell-culture supernatants. 
Cytokine secretion by MDDCs and MDMs was not induced by SAGEs, whilst treatment of the cells 
with the positive control of lipopolysaccharide (LPS) increased the amounts of TNF-α, IL-6, IL-1β, 
IL-10, IL-12p70 and IL-1α secreted (Figure S11a). Whilst phagocytic cells were shown to 
upregulate the co-stimulatory molecule CD80, and MHC class I and II expression was observed, 
these effects were moderate in comparison to the effects of LPS (Figure S11b).  
In combination, these experiments confirm that both MDMs and MDDCs internalize SAGE 
particles and are weakly activated by them, demonstrating the potential of SAGEs as a delivery 




Figure 4: Parent SAGEs are internalized by antigen presenting cells. Uptake of fluorescently 
labelled parent SAGEs by MDDCs (open circles) or MDMs (filled circles) quantified by flow 
cytometry. Conditions: 10 µM FITCSAGE in PBS (pH 7.4); n = 2 donors.  
 
2.4 TT-functionalized SAGEs drive a CD4+ T cell response in vitro 
We tested whether TT-functionalized SAGE would alter phagocytic uptake and downstream 
antigen-specific responses using PBMCs and flow cytometry as before. Compared to the previous 
experiment (Figure 4) we observed enhanced uptake of the parent SAGE by MDMs (Figure 5a), 
most likely due to donor variability. FITCSAGE-TT were taken up as effectively as parent SAGEs 
after 120 min, while TT-FITCSAGE and TT-FITCSAGE-TT were taken up significantly less well by 
this timepoint (Figure 5a). By the final timepoint, constructs with TT functionality at the N-
terminus of CC-Tri3 were internalized by MDDCs less rapidly than those functionalized at the C-
terminus. Consistent with our working model for SAGE assembly and structure, if the surface of the 
particle has been altered by the N-terminal modifications this has possibly affected particle uptake 
by MDDCs.  
To test whether differences in uptake of functionalized SAGE affected downstream antigen-
specific responses, the proliferative ability of human PBMCs was determined after exposure to each 
of the three TT-functionalized SAGEs for up to seven days (Figure 5b). PBMC proliferation is 
indicative of a T cell response and, in this case, considered to be a CD4+ T cell response against the 
TT peptide, a model CD4+ T cell epitope.[38] Experimental controls of parent SAGE, free TT 
 
 
peptide, and parent SAGE mixed with free TT peptide elicited low levels of cellular proliferation. 
TT-SAGE and SAGE-TT have an equivalent amount of TT as both parent SAGE + TT and free TT 
peptide in the controls. The amount of SAGE peptide is equivalent for all constructs and controls, 
and so TT-SAGE-TT has double the amount of TT relative to its singly functionalized counterparts. 
Two of the constructs, TT-SAGE-TT and SAGE-TT, induced a significantly greater proliferative 
response than free TT peptide. The doubly functionalized TT-SAGE-TT induced higher 
proliferative responses than those singly functionalized, though this difference was not significant. 
Here, the N-terminal functionality in TT-SAGE-TT is suspected of affecting its internalization. 
Despite delivering the same dosage, there was a significant difference in the response to TT-SAGE 
and SAGE-TT. We conclude that the less effective uptake of TT-SAGE impacts the downstream 
antigen-specific proliferative response. 
The results of these in vitro experiments confirm that APCs are able to internalize 
functionalized SAGEs, and to drive a downstream antigen-specific response. These data provide the 








Figure 5: TT-functionalized SAGEs drive an antigen-specific response in vitro. a Uptake of 
fluorescently labelled parent (black) and TT-functionalized SAGEs (TT-FITCSAGE in blue, 
FITCSAGE-TT in green, TT-FITCSAGE-TT in red) by MDDCs quantified by flow cytometry. 
Conditions: 10 µM FITCSAGE in PBS (pH 7.4); n = 6 donors. b Peak proliferative response of PBMCs 
to TT-functionalized SAGEs compared to a range of controls (free TT peptide in open circles, parent 
SAGE in black, parent SAGE mixed with free TT peptide in crossed circles) over a period of 10 days. 
Conditions: 7.5 µM TT-functionalized SAGE and equivalent control conditions in PBS (pH 7.4); n = 
14 donors. ** P < 0.01, *** P < 0.001. 
 
2.5 OVA-functionalized SAGEs drive CD4+ T cell and antibody responses in vivo  
Before testing for an antigen-specific response in vivo, the immunogenicity of parent SAGEs in an 
animal model was assessed by immunization in a prime/boost regimen. Groups of BALB/c mice 
were either immunized with 25 µg of parent SAGE at day 0 (d0) or day 0 and day 21 (d0 + d21), 
before assaying splenocyte proliferation and antibody titres. Animals immunized with a booster 
dose of SAGE showed an increased proliferation of SAGE-specific splenocytes when restimulated 
ex vivo with SAGE particles (Figure 6a). Furthermore, the prime/boost regimen also generated a 
significant increase in the production of anti-SAGE antibodies following a single immunization 
(Figure 6b). Based on these results, experiments with functionalized SAGEs were also performed 
with a prime/boost regimen in order to bolster the desired immune response. 
OVA-functionalized SAGEs were designed and synthesized to contain either N- or C-
terminal epitopes. Following the promising results observed with TT-SAGE-TT, two copies of the 
OVA epitope were conjugated to CC-Tri3 to increase the delivered dose. BALB/c mice were 
 
 
primed on d0 and boosted on d21 with a 160 µg dose of OVA, either in the form of OVA-
functionalized SAGE or free OVA peptide. The free peptide was delivered both with and without 
Complete Freund’s Adjuvant (CFA), in addition to a further control group immunized with parent 
SAGE. Splenocyte proliferation was monitored as a measure of T cell proliferation,[39] in this case 
that of CD4+ T cells in response to the OVA antigen. Splenocytes from mice given SAGE in any 
form were able to generate an anti-SAGE proliferative response when restimulated with SAGE ex 
vivo (Figure 6c) and produced anti-SAGE antibodies (Figure 6d). A low-level anti-SAGE antibody 
response was also observed in mice immunized with OVA + CFA, despite not receiving SAGE in 
any form. We believe this was due to the use of the adjuvant, resulting in an overall higher 
concentration of antibodies in the sera, and in turn a low level of non-specific binding. In parallel, 
splenocytes were also restimulated ex vivo with OVA peptide (Figure 6e). Mice given free OVA 
peptide with CFA mounted the strongest anti-OVA proliferative response, which is expected from 
the use of the adjuvant. However, the response against free OVA peptide without CFA was 
enhanced by immunizing with an equivalent dose in the form of OVA-functionalized SAGE 
particles. Mice given OVA-functionalized SAGE also produced OVA-specific antibodies (Figure 
6f). Whilst the positive control of free OVA peptide with CFA generated the greatest antibody 
titres, OVA-functionalized SAGE gave a significantly greater response than the free OVA peptide. 
This result demonstrates the potential of the SAGE system as a delivery platform capable of 
enhancing an immune response when compared to equivalent amounts of the free immunogenic 
peptide. 
A greater response, both in terms of CD4+ T cell proliferation and antibody production, was 
observed when OVA was delivered as part of a functionalized SAGE than as a free peptide. While 
OVA-SAGE stimulated a stronger CD4+ T cell proliferative response (Figure 5e), SAGE-OVA 
stimulated greater antibody production (Figure 5f). Whilst these results are contradictory, OVA-




These experiments demonstrate the effective uptake and processing of functionalized 
SAGEs in vivo, driving an antigen-specific response. The ability to drive both a CD4+ T cell and 








Figure 6: Parent SAGEs benefit from a prime/boost immunization schedule, and OVA-
functionalized SAGEs drive an antigen-specific response in vivo. a Proliferation of murine 
splenocytes after either a single (prime, filled circles) or booster (boost, open circles) immunization 
of parent SAGE. n = 6 mice (2 groups of 3, solid and dashed lines). b EPT ELISA using parent SAGE 
as antigen to monitor antibody production in the prime (closed circles) and boost (open circles) 
groups. c Proliferation of murine splenocytes isolated after booster immunizations, restimulating ex 
vivo with parent SAGE. d EPT ELISA using parent SAGE as antigen to monitor anti-SAGE antibody 
production. e Proliferation of murine splenocytes isolated after booster immunizations, restimulating 
ex vivo with OVA peptide. f EPT ELISA using OVA peptide as antigen to monitor anti-OVA antibody 
production. a-b n = 6 mice, each immunized with 25 µg of parent SAGE in PBS (pH 7.4) in a 
prime/boost schedule (d0 and d21). c-f n = 6 mice, each immunized with 160 µg of OVA either in 
the form of functionalized SAGE or free peptide in PBS (pH 7.4) in a prime/boost schedule (d0 and 
d21). Parent SAGE control at equivalent amount to OVA-functionalized SAGE conditions. 
Immunization with SAGE-OVA (orange), OVA-SAGE (purple), OVA peptide (open circles), OVA 





2.6 SAGE-HA drives a CD8+ T cell response in vivo 
Next, SAGEs were functionalized with the MHC class I epitope to test whether or not this platform 
could also enhance priming of naïve CD8+ T cell responses in vivo. Transgenic mice were used to 
test for this response to SAGEs functionalized with the extended HA.[40] SAGEs were 
functionalized with a single copy of HA at just the C terminus of CC-Tri3, as MHC class I 
processing is more specific than the MHC class II so far tested and positioning of the epitope has 
more of an effect on processing.[35] To this end, we utilized transgenic clone 4 (CL4) CD8+ T cells, 
which express a high-affinity T cell receptor (TcR) for the HA epitope. Accordingly, magnetic-
activated cell sorting (MACS)-purified naïve CL4 CD8+ T cells were labelled with the proliferation 
marker CellTraceTM Violet (CTV). As the CTV-labelled (CTV-CL4) cells divide after priming, 
daughter cells will contain less of the label and so will become distinguishable from undivided, 
fully-labelled unprimed CTV-CL4 cells. Naïve BALB/c mice were injected intravenously (i.v.) with 
purified CTV-CL4 cells. Mice were simultaneously immunized subcutaneously (s.c.) with either the 
HA peptide alone or SAGE-HA at 200 nM or 2 µM (delivering 19 ng or 188 ng of HA per mouse, 
respectively) to establish an appropriate dose. The use of transgenic T cells allowed for greatly 
reduced doses compared to previous experiments, as these cells are primed to respond to this 
particular epitope. After 3 days, the CTV-labelled CL4 cells (CTV-CL4) were isolated from the 
spleens of these mice, and the extent of proliferation was determined by flow cytometric analyses of 
CTV expression. The data show that in mice immunized with HA peptide alone, CL4 T cells 
proliferated in response to both concentrations of the peptide. This is evidenced by a shift of CTV-
labelled cells to the left of the panel as a result of the loss of CTV (Figure 7a). However, in mice 
immunized with SAGE-HA there was even greater CL4 T cell proliferation, at both concentrations, 
compared with mice immunized with HA peptide alone. This is evidenced by the appearance of a 
discrete population of highly-divided cells (Figure 7a; left of the dashed line). Indeed, further 
analyses with either the HA peptide or with SAGE-HA (both at 2 µM) showed that there was a 
 
 
significant increase in the percentage of these highly-divided cells in mice immunized with SAGE-
HA compared with immunization of HA alone (Figure 7b). 
 These data therefore demonstrate that functionalizing SAGE with the hemagglutinin518-526 
epitope enhances its delivery in vivo. 
Collectively, the results obtained using HA- and OVA-functionalized SAGEs show that 
SAGEs are capable of enhancing a range of different immune responses in vivo. 
 
 
Figure 7: HA-functionalized SAGEs drive a greater CD8+ T cell response than equivalent free 
peptide in vivo. a Proliferation of CTV-CL4 cells isolated from mice simultaneously immunized with 
CTV-CL4 cells (3 x 106 cells, 100 μl i.v.) and HA or SAGE-HA (100 µl of 200 nM or 2 µM s.c.). 
Highly divided cells were determined from cells past the gating threshold (dotted line). n = 1 mouse 
per condition. b Percentage of highly divided cells in each mouse immunized with SAGE-HA or HA. 
Average value for SAGE-HA is 24.0 % ± 14.6 %, and for HA is 9.1 % ± 4.6 %. Data from 
immunization with CTV-CL4 cells (3 x 106 cells, 100 μl i.v.) and SAGE-HA (filled circles: 100 µl of 
2 µM s.c., n = 5 mice) or HA (open circles: 100 µl of 2 µM s.c., n = 4 mice). 100 µl of 200 nM or 








The work described herein explores one potential application of self-assembling peptide cages 
(SAGEs), nanoparticles comprising de novo α-helical coiled-coil peptides. Subunit vaccines, instead 
of using the whole pathogen, utilize a scaffold to deliver pathogenic components. The use of 
SAGEs as such a scaffold offers a synthetic biology approach to subunit vaccine development, 
where the protein cages can be modified to deliver immunogenic components. The modularity of 
SAGEs allows for control over dose and delivery, in addition to the possibility of a multivalent 
system. 
We have demonstrated the potential of SAGEs to act as an antigen delivery platform 
through in vitro and in vivo toxicity assays, ex vivo immunogenic screens, and the use of 
functionalized SAGEs to probe a range of immune responses against model antigenic peptides.  
In vitro experiments using the model tetanus toxoid antigen (TT) confirm that antigen-
presenting cells (APCs) are able to internalize functionalized SAGEs, though the positioning of the 
functionalization may affect uptake. However, importantly, these experiments show that 
functionalized SAGEs are still internalized by monocyte-derived dendritic cells (MDDCs), and that 
these particles are effectively processed to drive a downstream antigen-specific CD4+ T cell 
response. In addition, the response to TT-functionalized SAGEs is greater than to an equivalent 
dose of free TT peptide. Future work looks to improve uptake consistency and enhance downstream 
responses, including targeting of MDDCs and cleavable linkers. 
SAGEs functionalized with the model ovalbumin antigen (OVA) are able to drive stronger 
immune responses in vivo than equivalent amounts of OVA peptide, including both CD4+ T cell and 
B cell responses. However, whilst we have demonstrated the ability to drive an antigen-specific 
response in vivo, our data with OVA-functionalized SAGEs highlight the need to increase the dose 
of antigen relative to SAGE per immunization. Ongoing work seeks to functionalize SAGEs with 
antigenic protein components to increase this ratio, so that peptides processed from the antigen rather 
than the SAGE form the majority of peptides presented at the APC surface. Dose-sparing is an 
 
 
important consideration for new vaccines to optimize economic and efficient immunization 
schedules. Further work should investigate the role of SAGE immunogenicity/mitogenicity in the 
antigen-specific response to establish if a prime/boost regimen is the most appropriate.  
We anticipate that to provide protection, the platform must be able to drive a range of immune 
responses. To build on the observed antigen-specific CD4+ T cell and B cell responses, we 
incorporated a CD8+ T cell epitope from the influenza virus hemagglutinin into the SAGE architecture 
via an extended peptide to enhance epitope delivery (HA). By adoptive transfer we assayed the 
proliferative response of transgenic T cells primed to recognise this epitope. We are encouraged by 
the increased response relative to free HA peptide and believe that the added ability to enhance a 
CD8+ T cell response gives the system potential as a vaccine scaffold. With further optimization, we 
anticipate exploiting the modularity of the system to target multiple branches of the immune system 
to protect against a challenge. This might take the form of particles comprising hubs with multiple 
antigenic functionalities, or the use of whole protein functionality to increase the immunogenic 
response. Lyophilization of particles functionalized with whole proteins must then be investigated, 
as the work described herein has used antigenic peptides, demonstrated to withstand this process. 
Positioning of the SAGE functionality and its effect on uptake and, importantly, downstream 
responses are areas which future work will investigate further. Based on the stricter processing of 
MHC class I antigens reflected in the work by de Haan et al.,[35] the HA epitope was only incorporated 
C-terminally in SAGEs. However, SAGES were functionalized with TT and OVA both N- and C-
terminally to allow for comparison of the effects of antigen positioning on downstream immune 
responses. The in vitro experiments with TT-functionalized SAGEs suggested that N-terminal 
functionalization decreased the uptake of SAGE, leading to a diminished ability to stimulate CD4+ T 
cell proliferation. By contrast, SAGEs functionalized N-terminally with OVA stimulated a stronger 
CD4+ T cell proliferative response, but weaker antibody response compared to SAGEs functionalized 
C-terminally with OVA. Whilst OVA-functionalized SAGE uptake by APCs has not been explored 
in as much detail as with TT functionality, these results suggest that N-terminal OVA does not affect 
 
 
uptake levels in the same way that N-terminal TT does, as measured by downstream immune 
responses. We know from biophysical characterization that OVA functionality leads to the formation 
of larger particles and has a potentially destabilizing effect on component trimerization, and so it 
would be of interest to further probe the mechanism of internalization. Whether functionalization 
affects particle recognition and cellular uptake due to surface charge, differences in particle size or 
aggregation remains to be identified. 
The de novo designed SAGE system provides an adaptable and predictable modular system 
that has easily accessible and interchangeable component parts. These components can be accessed 
synthetically or recombinantly, are not susceptible to problems associated with the cold chain and 
can be modified to successfully display antigens. The modularity of SAGEs means there is future 
potential for optimization in terms of charge, shape and size to drive the ideal antigen-specific 
response. In addition, the display of antigenic components can take the form of peptides or 
proteins,[31a] whether linear, conformational or conjugated, to best promote the uptake, delivery and 
presentation of viral or bacterial antigens to the immune system. To date we have demonstrated that 
SAGE particles can act as successful scaffolds for the presentation of immunogenic peptide 
components, whilst maintaining their ability to self-assemble. We now seek to explore whether 
SAGEs can be used as a novel delivery system to drive further antigen-specific responses, and 
whether functionalizing with whole proteins helps to strengthen these responses. Finally, whether 
with continued peptide functionality or with whole proteins, the next important step will be to use 
SAGEs as a scaffold to effectively protect against an infection challenge. 
 
4. Experimental Section 
Solid-phase peptide synthesis (SPPS): Peptides were synthesized using a Liberty Blue 
microwave peptide synthesizer (CEM, Mathews, USA) on a 0.1 mmol scale, using 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry. Coupling was performed using N,N’-
diisopropylcarbodiimide (DIC, 1 M in N,N-Dimethylformamide (DMF)) and 6-chloro-1-
 
 
hydroxybenzotriazole (Cl-HOBT, 0.5 M in DMF), with morpholine (20 % in DMF) for 
deprotection. In all instances deprotection conditions were two treatments of 80 °C with 45 W for 
300 s, with DMF washing in between. For Cys and His residues coupling conditions were 25 °C 
with 0 W for 120 s, followed by 50 °C with 25 W for 480 s. For Arg residues coupling conditions 
were 25 °C with 0 W for 2700 s, followed by 75 °C with 30 W for 120 s. For all other residues 
coupling conditions were 80 °C with 25 W for 300 s. 
SAGE assembly: Hub variants were dissolved at the desired concentration, in the desired 
buffer, and left for 10 min before mixing. If assembling with more than one variant, for example the 
two HubB variants for FITCSAGE, the two were mixed and left for 10 min before introducing the 
partner hub component. Mixed hubs were allowed to assemble for 1 h before conducting 
characterization and experiments. 
Circular dichroism (CD) spectroscopy: CD spectra were obtained using a JASCO J-810 or 
J-815 spectropolarimeter fitted with a Peltier temperature controller. Solutions were prepared (50 
µM) in PBS (pH 7.4) and examined in a 1 mm quartz cuvette. Thermal denaturation experiments 
were performed by increasing the temperature from 5 °C to 90 °C at a rate of 40 °C h-1. Spectra 
were measured at 5 °C intervals and the CD at 222 nm recorded at 1 °C intervals (1 nm intervals, 
1 nm bandwidth, 16 s response time). Raw data (mdeg) were normalized for peptide concentration, 
pathlength and the number of amide bonds to give mean residue ellipticity (MRE, deg cm2 dmol-1 
res-1). Melting temperatures were obtained from the intercept of the x axis in a second derivative 
plot of MRE at 222 nm against temperature. 
Scanning electron microscopy (SEM): Hubs were prepared in PBS (50 µM, pH 7.4) and 
mixed in a 1:1 ratio, allowing for SAGE assembly over 1 h (final total peptide concentration of 
50 µM). Assembled SAGE (5 µl) was then deposited onto a carbon-coated stub and left overnight 
to air-dry, before sputter coating with gold/palladium (Emitech K575X, 30 s at 40 mA) to deposit a 




AST assay: For the toxicity study, AST was evaluated in whole blood samples tested with a 
colorimetric method using a Konelab Prime 60i (Thermo Fisher). 
 Cellular uptake of fluorescent SAGE: Differentiated MDMs and MDDCs were seeded at 
equal densities of 5x105 per well in a 24 well plate, cells were washed with PBS prior to the 
addition of fluorescein isothiocyanate (FITC, 10 µM final concentration) functionalized particles 
(FITCSAGE) or left untreated for 0, 30, 90, 120 and 240 min. Cells were harvested on ice, manually 
detached and divided into two samples, trypan blue added to one sample (0.1% v/v final 
concentration) 15 min prior to flow cytometric acquisition in order to quench external fluorescence. 
Flow cytometry was performed using a LSRFortessa X-20 (BD Biosciences, San Diego, US). 
Analysis of unquenched versus quenched samples was performed using FlowJo software (BD 
Biosciences) and uptake of SAGE measured as Geomean fluorescence. 
Cell proliferation assays: For TT-functionalized SAGE experiments, healthy donors aged 
18-55 were recruited to the study and peripheral blood was obtained from these individuals. The 
study was approved by the local research ethics committee as part of the University of Bristol 
Immunity and Infection Research Tissue Bank (NHS REC 08/H0106/132; Licence no. 12248) and 
informed written consent was obtained from the donors in each case.  
Human PBMC or murine splenocytes were grown in 24-well flat-bottomed plates (Corning, 
UK) in the presence of SAGE (2, 7.5 or 15 µM), PHA (10 µg ml-1; Sigma) or media only and were 
placed at 37 ⁰C, 5 % CO2 in a humidified environment for up to 10 days. Between days 3-10 of 
culture, triplicate samples (100 µl) from the resuspended cell cultures were plated into 96-well 
round bottomed plates (Corning, UK). Cultures were pulsed with 0.4 µCi [3H]- thymidine (Perkin 
Elmer, UK) overnight before harvesting using a 96-well harvester (Tomtec, USA) and assessment 
of [3H]-thymidine incorporation using a Wallac Trilux 1450 β-scintillation counter (Perkin Elmer, 
UK). Proliferation was calculated as mean corrected counts per minute (CPM) for each triplicate. 
SAGE at 2, 7.5 and 15 µM is the equivalent of 12, 45 and 90 µg ml-1 total peptide respectively. 
 
 
 Immunization with OVA-functionalized SAGE: BALB/c mice (Jackson Laboratory, Charles 
River UK Limited) were used, where female mice were housed under specific pathogen free 
conditions in the University of Bristol Animal Services Unit and used at 12-16 weeks of age. All 
experiments were conducted in compliance with UK Home Office regulations.  
Mice were immunized subcutaneously. On termination spleens were excised from animals 
and sieved through a series of cell strainers (40 µm; BD Biosciences) to generate a single-cell 
suspension of murine splenocytes for ex vivo proliferation assays. After harvesting by 
centrifugation, the splenocytes were reconstituted in X-vivo 15 media (Lonza, Slough, UK) at 
1 × 106 cells ml-1 and stimulated with either SAGE or OVA peptide. Antibody titers against SAGE 
and OVA were evaluated using end point titre enzyme-linked immunosorbent assay (EPT ELISA), 
and cell proliferation assays carried out as in in vitro experiments. 
Labelling CL4 CD8+ T cells with CellTraceTM Violet (CTV): Proliferative assays were 
performed by labelling CL4 CD8+ cells with cell replication tracking CTV (Thermo Fisher). 
Enriched CL4 CD8+ cells were resuspended (4 x 106 cells ml-1 in PBS), then CTV (1 μl ml-1) was 
added and incubated in the dark (20 min at 37 °C). The labelling was quenched with CM and cells 
left to settle (30 min at room temperature) before being resuspended in CM for in vitro cultures 
(2 x 106 cells ml-1), or PBS for in vivo experiments (3-5 x 106 cells ml-1, 100 μl per mouse). 
Adoptive Transfer of CL4 CD8+ T cells and SAGE-HA immunization in vivo: 6- to 8-week 
old Thy1.1+/+ CL4+/- BALB/c TcR transgenic mice (recognising the hemagglutinin518-526 epitope; 
bred in a pathogen-free environment at the University of Bristol Animal Services Unit) and 
Thy1.2+/+ BALB/c mice (Charles River UK Limited) were used.  All experiments were conducted 
in accordance with current UK Home Office regulations.  
CL4 CD8+ T cells labelled with CTV were resuspended in PBS (50 % CTV-CL4 cells and 
50 % PBS). BALB/c mice were injected intravenously (i.v.) with CTV-CL4 cells (3-
5 x 106 cells, 100 μl i.v. per mouse), HA peptide (100 µl at 2 µM subcutaneously in dorsal neck 
scruff) or SAGE-HA (100 µl at 2 µM subcutaneously in dorsal neck scruff). 100 µl at 2 µM gives a 
 
 
188 ng dose of HA epitope. Mice were assigned treatments in a manner designed to eliminate batch 
effects. After 3 days spleens were extracted from the mice, processed and enriched for CL4 cells, 
then stained for viability and cell surface markers. 
Statistical analysis: Statistical analyses and graphical presentation were performed using 
GraphPad Prism 5 software. Significance of MDDC uptake of TT-functionalized SAGEs was 
determined by a 2 way ANOVA test (n = 6 donors). Significance of proliferative response to TT-
functionalized SAGEs was determined by a Mann-Whitney test (n = 14 donors). Significance of 
immunisation with OVA-functionalized SAGEs was determined by a Mann-Whitney test (n = 6 
donors). Significance of proliferative response to immunization with SAGE-HA was determined 
using a Welch’s t test after an arcsine square root transformation of the data. Asterisks indicate 
significant differences (* P < 0.05, ** P < 0.01, *** P < 0.001). 
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Materials and methods 
Peptide synthesis materials: N,N-Dimethylformamide (DMF), 6-chloro-1-
hydroxybenzotriazole (Cl-HOBT), diisopropylethylamine (DIPEA) and all L-amino acids were 
purchased from Cambridge Reagents Ltd (Hessle, UK). Resins were purchased from Merck 
Chemicals Ltd (Southampton, UK) and PCAS BioMatrix Inc (Quebec, Canada). Trifluoroacetic 
acid (TFA) and morpholine were purchased from Alfa Aesar (Massachusetts, USA). Aldrithiol-2 
was purchased from Sigma-Aldrich (Missouri, USA). Diethyl ether was purchased from Honeywell 
(New Jersey, USA). Dichloromethane (DCM) and acetonitrile (MeCN) were purchased from VWR 
International (Pennsylvania, USA). N,N’-diisopropylcarbodiimide (DIC) and triisopropylsilane 
(TIPS) were purchased from Acros Organics (New Jersey, USA). 
Peptide cleavage and purification: Peptides without added N-terminal functionality were 
acetylated on-resin by treating with acetic anhydride (3 eq), DIPEA (4.5 eq) and DMF (7 ml) for 
20 min. Regardless of capping, the resin was washed with DCM (3 x 10 ml) and dried prior to 
peptide cleavage. Peptides were cleaved from the resin by treatment with a cleavage cocktail of 
TFA (95 %), TIPS (2.5 %) and H2O (2.5 %) for 3 h with agitation. After filtering the suspended 
resin and evaporating the TFA, the peptide was precipitated in cold diethyl ether and pelleted by 
centrifuging. The peptide was dissolved in high-performance liquid chromatography (HPLC) 
 
 
buffers (90 % MeCN with 0.1 % TFA in H2O, and 0.1 % TFA in H2O) and lyophilized. Successful 
syntheses were determined by matrix assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS; Bruker ultrafleXtreme, USA), using α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix (10 mg ml-1 in H2O:MeCN:TFA 50:50:0.1) and generally ion positive reflector 
mode, and then centrifuged (20 °C at 3000 rpm for 10 min) prior to purification to pellet insoluble 
material. Purification was achieved by reversed-phase (RP)-HPLC using a JASCO (Oklahoma, 
USA) chromatography system with either a preparative (Grace Vydac 218TP 5 µ C18, 300 Å, 150 x 
4.6 mm) or semi-preparative (Phenomenex Luna 5 µ C18, 100 Å, 150 x 10 mm) column, eluting 
with linear gradients and a flow rate of 8 ml min-1 or 3 ml min-1 respectively. Buffer A = 0.1 % TFA 
in H2O, buffer B = 0.1 % TFA in 90 % MeCN. Fractions were again analysed by MALDI-TOF MS, 
and their purity assessed by RP-HPLC using an analytical (Phenomenex Kinetex 5 µ C18, 100 Å, 
100 x 4.6 mm) column before lyophilising. 
Disulfide bond formation: Activation of Cys residues was achieved by a 30 min treatment of 
peptide (1 mg ml-1 in H2O, 10 mg scale) with aldrithiol-2 (10 eq in methanol, 1 ml/10 ml dissolved 
peptide) followed by extraction of any unreacted aldrithiol-2 with Et2O (3 x 20 ml washing). The 
aqueous portion was then freeze-dried before analysing and purifying as in the initial work up. 
Formation of hubs by disulfide formation was achieved by mixing this activated peptide with either 
CC-Di-A or CC-Di-B for 1 h in phosphate buffered saline (PBS; NaCl (137 mM), KCl (2.7 mM), 
and phosphate buffer (10 mM)) at pH 7.4. Successful hub assembly was confirmed by MALDI-
TOF mass spectrometry, and further purified as before.  
Determining peptide concentration: Peptide concentrations were determined by UV 
absorption at 280 nm (ε280 Trp = 5690 mol-1 cm-1; ε280 Tyr = 1280 mol-1 cm-1) using a Thermo 
Scientific NanoDrop 2000 spectrophotometer. Concentrations of samples not containing a 
chromophore used a literature protocol[41] to determine the absorbance at 214 nm (ε214 OVA = 
26825 mol-1 cm-1). 
 
 
Dynamic light scattering (DLS): The hydrodynamic diameter of hubs and assembled SAGEs 
were determined using a Malvern (Malvern, UK) Zetasizer Nanoseries instrument. Samples were 
prepared at 10 µM in PBS (pH 7.4). Data were collected over 10 min (10 repeat analyses of 10 x 
6 s) at 20 °C and analysed using the associated DTS Nano Particle sizing software. 
Analytical ultracentrifugation (AUC) sedimentation velocity experiments: Sedimentation 
velocity experiments were carried out using a Beckman Coulter Optima XL-A analytical 
ultracentrifuge with an An-60 Ti rotor, spinning at 60,000 rpm at 20 °C. A total of 120 absorbance 
scans were collected at 5 min intervals at an appropriate wavelength monitoring the peptide 
backbone for each sample, over a radial range of 5.8 to 7.3 cm. Peptides were prepared at 50 µM in 
PBS (pH 7.4). Data were fitted to a continuous c(s) distribution at 95 % confidence using Sedfit[42]. 
The density of the buffer was calculated using Sednterp (http://rasmb.org/sednterp/), and the partial 
specific volume of each trimer peptide was calculated using Sedfit: CC-Tri3 (0.7622 ml g-1); TT-
CC-Tri3 (0.7625 ml g-1); CC-Tri3- TT (0.7625 ml g-1); TT-CC-Tri3-TT (0.7626 ml g-1); OVA-CC-
Tri3 (0.7329 ml g-1); CC-Tri3-OVA (0.7329 ml g-1); CC-Tri3-HA (0.74933 ml g-1). 
Human peripheral blood mononuclear cells: Human peripheral blood mononuclear cells 
(PBMCs) were isolated from the blood of healthy donors by centrifugation at 700 g for 20 min on 
Histopaque density-gradient medium (Sigma). PBMCs were harvested, washed in Hanks’ balanced 
salt solution (Invitrogen) and resuspended in complete RPMI (RPMI-1640 with penicillin 
(100 U ml-1), streptomycin (0.1 mg ml-1), L-glutamine (4 mM) and HEPES buffer (10 mM)). 
PBMCs were counted using trypan blue (0.4 % wt/vol; Sigma), reconstituted in complete RPMI at 
1 × 106 cells ml-1 with heat-inactivated human AB-serum (10 % vol/vol; Sigma), and incubated at 
37 °C in CO2 (5 %). 
To produce monocyte-derived dendritic cells (MDDCs) and macrophages (MDMs), 
monocytes were first isolated from the PBMCs by negative selection using a Macs Monocyte 
Isolation Kit II, following the manufacturer’s guidelines (Miltenyi Biotec Ltd., Bisley, UK), with a 
final purity of ˃80 %. Monocytes were reconstituted in complete RPMI and seeded at 
 
 
1 x 106 cells ml-1 in recombinant human GM-CSF (rhGM-CSF, final concentration of 1000 U ml-1; 
R&D Systems, Abingdon, UK) and rhIL-4 (500 U ml-1) for differentiation into MDDCs or rhGM-
CSF (50 U ml-1; Miltenyi Biotec) and rhm-CSF (50 ng ml-1; Miltenyi Biotec) for differentiation into 
MDMs. Cells were incubated at 37 °C in CO2 (5 %) for 5 days. 
 Phagocytic phenotyping and cytokine analysis with MDDCs and MDMs: After 5 days of 
differentiation, MDDCs and MDCs were incubated with media only, SAGE (10 µM) or 
lipopolysaccharide (LPS, 100 ng ml-1; Sigma). Supernatants were removed from cell cultures after 
48 h, centrifuged to remove any cell debris and stored at -80 ⁰C for subsequent analysis. Cells were 
harvested from the wells and expression of surface markers associated with cell activation and 
antigen presentation were assessed using the following antibodies: CD80–FITC, CD83-PE, CD25-
PE-Cy5, CD86-PE-Cy7, HLA A,B,C-PB, HLA-DR-APC (Biolegend, London, UK).  Flow 
cytometry was performed using a LSRFortessa X-20, 5000-10,000 cell events were collected and 
analysis performed using FlowJo software and fluorescence expressed as Geomean fluorescence. 
Cytokine production was assessed using a Multiplex human cytokine immunoassay kit (Millipore, 
UK) and analysed for the presence of TNF-α, IL-6, IL-1β, IL-10, IL-12p70 and IL-1α according to 
the manufacturer’s instructions. Samples were analysed using a Luminex 200 machine (Luminex B 
V, The Netherlands). 
End point titre enzyme-linked immunosorbent assay (EPT ELISA): Antibody titres against 
SAGE or OVA peptide were evaluated using EPT ELISA. Blood from human donors, or from 
BALB/c mice upon termination, was collected and centrifuged (3,000 g for 10 min). After 
separation, serum was extracted and stored at –20 °C for future analysis. Nunc Maxisorp 96 well 
plates (Sigma) were coated with capture antigen by overnight incubation at 4 °C with either SAGE 
(7.5 µM) or OVA peptide (10 µg ml-1) in PBS (pH 7.4). Plates were washed twice with PBS 
containing Tween (0.1 % v/v, PBS-T) before blocking with bovine serum albumin (BSA) in PBS 
(1% BSA-PBS; Sigma) for 1 h at 37 °C. The blocking reagent was removed and the plates washed 
twice with PBS-T before the adding serum at an initial dilution of 1 in 10 and then performing two-
 
 
fold dilutions across the plate. After 1 h incubation at room temperature, the plates were washed 
four times with PBS-T, followed by the addition of a goat anti-human or anti-mouse IgG:HRP 
(Serotec, Kidlington, UK) at a 1:2000 dilution in PBS-T and 1 h incubation at room temperature.  
Plates were then washed four times before adding citrate phosphate buffer supplemented with the 
substrate o-phenylenediamine dihydrochloride hydrogen peroxide (OPD, 0.4 mg ml-1, 30 %; 
Sigma). The plates were left to develop at room temperature before being stopped by 1 M H2SO4. 
The optical density was read at 490 nm and data was acquired and analysed using SoftMax Pro 
software (California, USA). 
Production of splenocytes from Clone-4 TcR transgenic (CL4) mice: Spleens were collected 
from CL4 TcR transgenic mice using sterile instruments and kept in RPMI. Spleens were sectioned, 
then pressed through cell strainers (40 μm; Corning). This process was repeated several times whilst 
washing with Complete Medium (CM: RPMI with L-glutamine (Thermo Fisher) supplemented with 
foetal bovine serum (10 %; Thermo Scientific), penicillin/streptomycin (50 U mL-1; Thermo Fisher) 
and β-mercaptoethanol (5 x 10-10 M; Sigma-Aldrich)). Red blood cells were lysed using ACK 
lysing buffer (1 ml per spleen; Thermo Fisher). Lysis was quenched after 3 min using CM (10 ml) 
then PBS (10 ml). 
  Magnetic-Activated Cell Sorting (MACS) for CD8+ T cells: Purified CL4 splenocytes were 
enriched for CD8+ T cells with MACS. The lymphocyte population was labelled with anti-CD8a 
MicroBeads (Miltenyi Biotec) in MACS buffer (PBS with BSA (5 %) and 
ethylenediaminetetraacetic acid (EDTA; 2 mM); 50 μl per spleen harvested) by incubating for 
15 min at 4 °C. After incubation, labelled cells were separated using a MidiMACS Separator 
(Miltenyi Biotec), MidiMACS LS columns (Miltenyi Biotec) and MACS buffer. Unbound beads 
were removed by adding MACS buffer (10 ml) and centrifuging (5 min at 1400 rpm at 4 °C). Cells 
were resuspended in MACS buffer and run through an LS column in a MidiMACS Separator pre-
washed with MACS buffer (6 ml). The eluent of the first flow-through was re-run to maximize 
 
 
CD8+ cell yield. After removal from the MidiMACS separator, CD8+ cells were removed by 
plunging MACS buffer (6 ml) through the LS column.  
CL4 CD8+ T cell gating: CTV-labelled clone-4 (Thy1.1+) CD8+ cells adoptively transferred 
into BALB/c mice (Thy1.2+) were selected for by gating for lymphocytes, single cells, live cells, 
CD8b+ and Thy1.1+. Density plots for CTV-labelled CL4 cells were generated by showing Thy1.1 
(y-axis) against CTV (x-axis). Histograms were generated by showing cell count (y-axis) against 
CTV (x-axis). 
CL4 CD8+ T cell viability staining: Zombie NIRTM Fixable Viability Kit (BioLegend, USA) 
was used to reveal dead cell populations. Staining was carried out by incubating the cells 
(resuspended in 100 μl PBS) with the prepared dye (1 μl for 1 x 106 cells) for 15 min at room 
temperature in the dark, before washing with FACS buffer (BSA (0.5 % (w/v); Sigma-Aldrich) in 
PBS).  
CL4 CD8+ T cell surface staining: Cell surface staining was performed using fluorochrome- 
conjugated monoclonal antibodies (mAbs). DB Fc blockTM (BD Biosciences, UK) was used to 
prevent non-specific binding of mAbs to Fc receptors on T cells (incubation for 15 min at 4 °C). 
Cells were then spun down and resuspended. The optimum volume of the following mAbs required 
for staining was then added (incubated in the dark at 4 °C for 30 min): CD8β-PE-Cy7, Thy1.1-
PerCP-Cy5.5 (Biolegend).  Cells were then washed with FACS buffer to remove any unbound 
antibody. Labelled cells were resuspended in paraformaldehyde (PFA; 1 %) for flow cytometric 






                                               gabcdef gabcdef gabcdef 
MW (Da) 
CC-Tri3                                           Ac-G EIAAIKK EIAAIKC EIAAIKQ GYG-NH 2630.11 
CC-Di-A                                           Ac-G EIAALEK ENAALEC EIAALEQ GWW-NH 2786.08 
CC-Di-B                                           Ac-G KIAALKK KNAALKC KIAALKQ GYW-NH 2757.39 
FITCCC-Tri3                                      FITC-GG G EIAAIKK EIAAIKC EIAAIKQ GYG-NH 3062.54 
TT-CC-Tri3                    H-IDKISDVSTIVPYIGPALNI GG G EIAAIKKEIAAIKCEIAAIKQGYG-NH 4812.63 
CC-Tri3-TT                                           Ac-G EIAAIKKEIAAIKCEIAAIKQGYG GG IDKISDVSTIVPYIGPALNI-OH 4855.65 
TT-CC-Tri3-TT                    H-IDKISDVSTIVPYIGPALNI GG G EIAAIKKEIAAIKCEIAAIKQGYG GG IDKISDVSTIVPYIGPALNI-OH 7038.16 
OVA-CC-Tri3  H-ISQAVHAAHAEINEAGR GG ISQAVHAAHAEINEAGR GG G EIAAIKKEIAAIKCEIAAIKQGYG-NH 6328.06 
CC-Tri3-OVA                                           Ac-G EIAAIKKEIAAIKCEIAAIKQGYG GG ISQAVHAAHAEINEAGR GG ISQAVHAAHAEINEAGR-OH 6371.08 
CC-Tri3-HA                                           Ac-G EIAAIKKEIAAIKCEIAAIKQGYG GG AVGAGATAEEIYSTVASSL-OH 4524.11 
TT H-IDKISDVSTIVPYIGPALNI-OH 2128.46 
OVA H-ISQAVHAAHAEINEAGR-OH 1773.90 
HA H-AVGAGATAEEIYSTVASSL-OH 1796.93 
 
Table S1: Details of synthesized peptides. Peptide name, sequence and molecular weight (MW; Da). Peptides synthesized by Fmoc-SPPS as 
described in the SI materials and methods. The termini were capped when the de novo sequence was terminal (N-terminal acetylation, C-terminal 
amidation). HA sequence in bold represents the influenza virus A/PR/8/34 (H1N1) hemagglutinin518-526 epitope sequence.
 
 





HubA CC-Tri3 CC-Di-A 5414.19 
HubB CC-Tri3 CC-Di-B 5385.50 
FITCHubB FITCCC-Tri3 CC-Di-B 5817.93 
TT-HubA TT-CC-Tri3 CC-Di-A 7596.71 
TT-HubB TT-CC-Tri3 CC-Di-B 7568.02 
HubA-TT CC-Tri3-TT CC-Di-A 7639.68 
HubB-TT CC-Tri3-TT CC-Di-B 7611.04 
TT-HubA-TT TT-CC-Tri3-TT CC-Di-A 9822.24 
TT-HubB-TT TT-CC-Tri3-TT CC-Di-B 9793.55 
OVA-HubA OVA-CC-Tri3 CC-Di-A 9112.14 
OVA-HubB OVA-CC-Tri3 CC-Di-B 9083.45 
HubA-OVA CC-Tri3-OVA CC-Di-A 9155.16 
HubB-OVA CC-Tri3-OVA CC-Di-B 9126.47 
HubA-HA CC-Tri3-HA CC-Di-A 7308.19 
HubB-HA CC-Tri3-HA CC-Di-B 7281.50 
 
Table S2: Details of prepared hub building blocks. Name, component peptides and MW of 
hub building blocks. The hubs were assembled by formation of a disulfide bond, as described 









SAGE name HubA variant HubB variant 
Parent SAGE HubA (50 %) HubB (50 %) 
FITCSAGE HubA (50 %) HubB (45 %) + FITCHubB (5 %) 
TT-SAGE TT-HubA (50 %) TT-HubB (50 %) 
SAGE-TT HubA-TT (50 %) HubB-TT (50 %) 
TT-SAGE-TT TT-HubA-TT (50 %) TT-HubB-TT (50 %) 
TT-FITCSAGE TT-HubA (50 %) TT-HubB (45 %) + FITCHubB (5 %) 
FITCSAGE-TT HubA-TT (50 %) HubB-TT (45 %) + FITCHubB (5 %) 
TT-FITCSAGE-TT TT-HubA-TT (50 %) TT-HubB-TT (45 %) + FITCHubB (5 %) 
OVA-SAGE OVA-HubA (50 %) OVA-HubB (50 %) 
SAGE-OVA 
SAGE-HA 
HubA-OVA (50 %) 
HubA-HA (50 %) 
HubB-OVA (50 %) 
HubB-HA (50 %) 
 
Table S3: Details of assembled SAGEs. Name and component hubs of assembled SAGE 
designs. Hub variants were separately dissolved in appropriate buffer and left for 10 min 












Figure S1: Analytical-HPLC for peptide components. a CC-Tri3 (20-80 % B in 9 min). b 
CC-Di-A (20-80 % B in 9 min). c CC-Di-B (20-80 % B in 9 min).  d TT-CC-Tri3 (20-80 % B 
in 9 min). e CC-Tri3-TT (30-80 % B in 9 min). f TT-CC-Tri3-TT (20-80 % B in 9 min). g 
OVA-CC-Tri3 (20-80 % B in 9 min). h CC-Tri3-OVA (20-80 % B in 9 min). i CC-Tri3-HA 
(30-80 % B in 9 min) j TT (20-80 % B in 9 min). k OVA (10-60 % B in 9 min). l HA (10-80 % 
B in 9 min). Conditions: Buffer A = 0.1 % TFA in H2O, buffer B = 0.1 % TFA in 90 % MeCN. 
Peptides dissolved in HPLC buffers and run on an analytical (Phenomenex Kinetex 5 µ C18, 





Figure S2: Analytical-HPLC for HubA variants. a HubA (20-80 % B in 9 min). b TT-HubA 
(20-80 % B in 9 min).  c HubA-TT (20-80 % B in 9 min). d TT-HubA-TT (20-80 % B in 
9 min). e OVA-HubA (20-80 % B in 9 min). f HubA-OVA (20-80 % B in 9 min). g HubA-HA 
(30-80 % B in 9 min). Conditions: Buffer A = 0.1 % TFA in H2O, buffer B = 0.1 % TFA in 
90 % MeCN. Peptides dissolved in HPLC buffers and run on an analytical (Phenomenex 





Figure S3: Analytical-HPLC for HubB variants. a HubB (20-80 % B in 9 min). b TT-HubB 
(20-80 % B in 9 min). c HubB-TT (20-80 % B in 9 min). d TT-HubB-TT (20-80 % B in 9 min). 
e OVA-HubB (20-80 % B in 9 min). f HubB-OVA (20-80 % B in 9 min). g HubB-HA (30-
80 % B in 9 min). Conditions: Buffer A = 0.1 % TFA in H2O, buffer B = 0.1 % TFA in 90 % 
MeCN. Peptides dissolved in HPLC buffers and run on an analytical (Phenomenex Kinetex 5 




Fig S4: MALDI-TOF MS for peptide components. a CC-Tri3 (expected = 2630.1 Da). b 
CC-Di-A (expected = 2786.1 Da). c CC-Di-B (expected = 2757.4 Da).  d TT-CC-Tri3 
(expected = 4812.6 Da). e CC-Tri3-TT (expected = 4855.7 Da). f TT-CC-Tri3-TT (expected = 
7038.2 Da). g OVA-CC-Tri3 (expected = 6328.1 Da). h CC-Tri3-OVA (expected = 
6371.1 Da). i CC-Tri3-HA (expected = 4524.1 Da). j TT (expected = 2128.5 Da). k OVA 
(expected = 1773.9 Da). l HA (expected = 1796.9 Da). Conditions: Peptides mixed with α-
cyano-4-hydroxycinnamic acid (CHCA) matrix (10 mg ml-1 in H2O:MeCN:TFA 50:50:0.1) 





Fig S5: MALDI-TOF MS for HubA variants. a HubA (expected = 5414.2 Da). b TT-HubA 
(expected = 7596.7 Da).  c HubA-TT (expected = 7639.7 Da). d TT-HubA-TT (expected = 
9822.2 Da). e OVA-HubA (expected = 9112.1 Da). f HubA-OVA (expected = 9155.2 Da). g 
HubA-HA (expected = 7308.2 Da). Conditions: Peptides mixed with α-cyano-4-
hydroxycinnamic acid (CHCA) matrix (10 mg ml-1 in H2O:MeCN:TFA 50:50:0.1) and 





Fig S6: MALDI-TOF MS for HubB variants. a HubB (expected = 5385.5 Da). b TT-HubB 
(expected = 7568.0 Da). c HubB-TT (expected = 7611.0 Da). d TT-HubB-TT (expected = 
9793.6 Da). e OVA-HubB (expected = 9083.5 Da). f HubB-OVA (expected = 9126.5 Da). g 
HubB-HA (expected = 7281.5 Da). Conditions: Peptides mixed with α-cyano-4-
hydroxycinnamic acid (CHCA) matrix (10 mg ml-1 in H2O:MeCN:TFA 50:50:0.1) and 

















CC-Tri3 55 -29556.41 79.3 -29556.41 79.3 
TT-CC-Tri3 61 -17646.45 45.0 -32469.46 81.9 
CC-Tri3-TT 51 -12444.69 32.0 -22400.39 56.8 
TT-CC-Tri3-TT 56 -9934.31 25.7 -27021.28 68.2 
OVA-CC-Tri3 55 -13153.92 33.8 -32621.71 82.2 
CC-Tri3-OVA 54 -10561.92 29.8 -26616.03 73.4 
CC-Tri3-HA 53 -14011.11 35.9 -25780.44 69.3 
 
Table S4: Circular dichroism (CD) data for each CC-Tri3 peptide synthesized. Midpoint 
of thermal unfolding (TM) of functionalized trimer peptides relative to parent as determined by 
CD spectroscopy when ramping the temperature from 5-90 °C at a rate of 40 °Ch-1; mean 
residue ellipticity (MRE) at 222 nm of each peptide at 5 °C; observed fraction helix as 
determined using: 
 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 ℎ𝑒𝑙𝑖𝑥 (%) = 100 (
([𝜃]222 − [𝜃]𝑐𝑜𝑖𝑙) 
(−42,500(1 − (3 𝑛⁄ )) − [𝜃]𝑐𝑜𝑖𝑙
) 
 
Where [θ]coil = 640-45T = 415 deg cm
2 dmol-1 res-1 at 5 °C, and n is the number of peptide 
bonds (including N terminal acetylation). These calculations are repeated using MRE values 
normalized to the length of the parent trimer (25 residues) to assess any impact on the degree 











Fig S7: CD data for hub variants. a 5 °C wavelength scans of HubA variants. b 5 °C 
wavelength scans of HubB variants. c Thermal denaturation curves of HubA variants. d 
Thermal denaturation curves of HubB variants. a-d conditions: hubs at 50 µM in PBS (pH 7.4). 
Comparison of parent hubs containing CC-Tri3 (black) with functionalized hubs containing 
TT-CC-Tri3 (blue), CC-Tri3-TT (green), TT-CC-Tri3-TT (red), OVA-CC-Tri3 (purple), CC-

















Parent 69 57 
TT-SAGE 72 68 
SAGE-TT 73 67 
TT-SAGE-TT 63 73 
OVA-SAGE 59 56 
SAGE-OVA 64 56 
SAGE-HA 72 62 
 
Table S5: Midpoint of thermal unfolding (TM) for functionalized hubs in each SAGE 
design. TM values of functionalized hub components when ramping the temperature from 5-













Fig S8: Analytical ultracentrifugation (AUC) data for each homotrimeric peptide. AUC 
SV data fits (top) and residuals (bottom) for functionalized trimer peptides. Continuous c(s) 
distribution from sedimentation-velocity data at 60 k rpm, 20 °C. a CC-Tri3, giving 8.47 kDa 
(3.2 x monomer mass). b TT-CC-Tri3, giving 14.1 kDa (2.9 x monomer mass). c CC-Tri3-TT, 
giving 13.1 kDa (2.7 x monomer mass). d TT-CC-Tri3-TT, giving 20.3 kDa (2.9 x monomer 
mass) and 7.12 kDa (monomer). e OVA-CC-Tri3, giving 12.2 kDa (1.9 x monomer mass). f 
CC-Tri3-OVA, giving 22.1 kDa (3.5 x monomer mass) and 10.1 kDa (1.6 x monomer mass). 




Figure S9: Dynamic light scattering (DLS) data for each SAGE design. Data were collected 
over 10 min (10 repeat analyses of 10 x 6 s) at 20 °C, allowing for plotting of hydrodynamic 
diameter against time. Hub components (HubA variant = dotted line, HubB variant = dashed 
line) and SAGE assembly (solid lines) were analysed. a parent SAGE. b TT-SAGE. c SAGE-
TT. d TT-SAGE-TT. e OVA-SAGE. f SAGE-OVA. g SAGE-HA. Hubs were prepared at 




Figure S10: Representation of cell populations during in vivo toxicity assay. Populations 
of B cells, monocytes, CD4 and CD8 T cells in peripheral blood isolated from control animals 
immunized with PBS (pH 7.4) alone and those immunized with parent SAGE. BALB/c mice 
were immunized with four doses (350 μg) of parent SAGE, each dose at an interval of 3 weeks 








1.1 Lung Five sections.  Each shows multifocal mild to moderate 
interstitial pneumonia.  One section shows a region of 
moderate peribronchiolar/arteriolar lymphoplasmacytic 




 Spleen Single section.  Normal to active white pulp with 








 Kidney Two sections.  Histologically normal kidney, including 




 Injection site One strip of skin including panniculus muscle, subcutis 
and deep muscle block.   There is diffuse mild to moderate 
dermal to subcutaneous oedema and focal 
microhaemorrhage, with chiefly pyogranulomatous 
 
 
inflammation and some focal lymphoplasmacytic 
aggregates (a).  There is thrombosis/vasculitis of some 
small vessels (d).  Immediately above the deep muscle 
block is a plaque of brightly eosinophilic particulate 
material (adjuvant material?) enveloped by primarily 






1.2 Lung Five sections of lung with mild to moderate interstitial 
pneumonia as above. 
 
 Spleen Single section of normal/reactive spleen as above. 
 
 Liver Five sections of liver with normal microarchitecture.  
There is focal mild portal fibrosis and bile duct 
proliferation associated with mild lymphoplasmacytic 
inflammation.  One section includes gall bladder which 





 Kidney Two sections of normal kidney including cortex and 
medulla. 
 
 Injection site Strip of skin with deep muscle block and underlying 
adipose tissue (a).  Diffuse oedema, microhaemorrhage 
and inflammation (neutrophils and macrophages with 
prominent erythrophagocytosis) in all layers (c).  
 
 
Vasculitis and thrombosis multiple, with focal 
myonecrosis of muscle block (b).  No eosinophilic 






1.3 Lung Five sections of lung with moderate interstitial pneumonia 
as described above. 
 
 Spleen One section of normal/reactive spleen as described above. 
 
 Liver Five sections of normal liver. 
 
 Kidney Two sections of normal kidney including cortex and 
medulla. 
 
 Injection site Strip of skin with similar range of changes to those 
described above, but slightly milder with fewer examples 
of vasculitis/thrombosis.  Single small area at one margin 
includes angular eosinophilic material with surrounding 




1.4 Lung Five sections of lung with mild to moderate interstitial 
pneumonia as above. 
 
 Spleen Section of normal/reactive spleen. 
 




 Kidney Two sections of normal kidney; cortex and medulla. 
 
 Injection site Strip of skin with changes as described above.  Diffuse 
dermal to subcutaneous oedema, microhaemorrhage and 
inflammation.  More prominent focal myositis and 
myonecrosis.  A plaque of eosinophilic material within the 







1.5 Lung Five sections of lung with moderate interstitial pneumonia 
as above. 
 
 Spleen Section of normal/reactive spleen.  Also includes a small 
portion of normal exocrine pancreas. 
 
 Liver Five sections of normal liver.  Occasional small portal 
aggregates of mixed mononuclear and granulocytic cells 
regarded as incidental. 
 
 Kidney Two sections of normal kidney; cortex and medulla. 
 
 Injection site Strip of largely normal skin.  The only change of note is 
the presence of a mild band of early fibroblastic 
proliferation and scattered inflammatory cells at the deep 






1.6 Lung Five sections of lung with moderate interstitial pneumonia 
as above. 
 
 Spleen One section of normal/reactive spleen. 
 
 Liver Five sections of normal liver.  Small portion of gall 
bladder with mild inflammatory change of the lamina 
propria. 
 
 Kidney Two sections of normal kidney; cortex and medulla. 
 
 Injection site Strip of skin with changes similar to 1.5, but with the 
addition of mild diffuse inflammation (granulocytes and 
macrophages) of the deep adipose tissue beneath the level 
of the band of mild fibrosis at the deep margin of the 
muscle block.  Additional band of fibrosis/inflammation 




2.1 Lung Five sections of lung.  Most of the tissue area is normal 
but with agonal haemorrhage.  There are only small areas 




 Spleen One section of normal/reactive spleen. 
 
 Liver Five sections of normal liver. 
 
 Kidney Two sections of normal kidney. 
 
 Injection site Section of essentially normal skin with central mild band 







2.2 Lung Five sections of lung with mild to moderate interstitial 
pneumonia. 
 
 Spleen Section of normal/reactive spleen and adjacent fragment of 
normal pancreas. 
 
 Liver Five sections of normal liver. 
 
 Kidney Two sections of normal kidney. 
 
 Injection site Section of normal skin but with light band of early 
fibroplasia immediately beneath deep muscle block.  No 
inflammatory change. 
 
2.3 Lung Five sections of lung with mild to moderate interstitial 
pneumonia. 
 
 Spleen Section of normal/reactive spleen. 
 
 Liver Five sections essentially normal liver; mild mononuclear 
inflammation in one portal area. 
 
 Kidney Two sections of normal kidney. 
 
 Injection site Section of normal skin with similar band of fibroplasia at 
base of deep muscle block. 
 
 
Table S6: Mouse histopathology from in vivo toxicity assay. BALB/c mice were 
immunized subcutaneously with four sequential doses of SAGE (350 µg in PBS (pH 7.4), 
n = 6 mice) or PBS (n = 3 mice) at 3 week intervals (2 weeks for the final immunisation). 
Histopathology results for each tissue analysis of each mouse 
 
General histopathology comments 
Group 1 (SAGE) has background changes only in the viscera.  Interstitial pneumonia is a 
common change in laboratory mice, related to housing on dusty bedding.  One animal had mild 
cholecystitis, also regarded as incidental.  The major change related to the injection site.  Four 
of six mice had prominent diffuse oedema, microhaemorrhage and moderate inflammation 
(dominated by granulocytes and macrophages).  There was also variable vasculitis/thrombosis 
 
 
and some focal myositis/myonecrosis of the deep muscle fibres.  These animals also had 
variable amounts of bright eosinophilic, angular (adjuvant?) material deposited at different 
levels of the skin and associated with surrounding inflammatory cells.  This is interpreted as 
the injected material.  Two of the five mice had only mild inflammation and early fibrosis 
within the adipose tissue beneath the deep muscle block (and in one case also within the 
hypodermis above this muscle block). 
 
Group 2 (PBS) has the same range of background changes in the viscera, although the lungs 
of one of these three animals is least affected by interstitial pneumonia.  The skin samples show 
no evidence of active inflammation or deposition of adjuvant material.  There is some mild 
fibroblastic activity at the base of the deep muscle block.  It is not clear whether this is a 
significant pathological change or a background process. 
 
Overall, the most significant changes in these samples are in the skin.  There is marked and 
diffuse inflammation associated with larger quantities of adjuvant material in group 1, but only 





Figure S11: Activation of antigen presenting cells. a PBMCs differentiated into MDDCs or 
MDMs were analysed for cytokine production related to activation or antigen presentation 
when exposed to parent SAGE or LPS. b PBMCs differentiated into MDDCs or MDMs were 
analysed for expression of surface markers related to activation or antigen presentation when 
exposed to parent SAGE or LPS. Conditions: parent SAGE at 10 µM in PBS (pH 7.4); LPS at 
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